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Summary
The mTOR kinase controls cell growth, proliferation,
and survival through two distinct multiprotein com-
plexes, mTORC1 and mTORC2. mTOR and mLST8
are in both complexes, while raptor and rictor are
part of only mTORC1 and mTORC2, respectively. To
investigate mTORC1 and mTORC2 function in vivo,
we generated mice deficient for raptor, rictor, or
mLST8. Like mice null formTOR, those lacking raptor
die early in development. However, mLST8 null em-
bryos survive until e10.5 and resemble embryos miss-
ing rictor. mLST8 is necessary to maintain the rictor-
mTOR, but not the raptor-mTOR, interaction, and
both mLST8 and rictor are required for the hydropho-
bic motif phosphorylation of Akt/PKB and PKCa, but
not S6K1. Furthermore, insulin signaling to FOXO3,
but not to TSC2 or GSK3b, requiresmLST8 and rictor.
Thus, mTORC1 function is essential in early develop-
ment, mLST8 is required only for mTORC2 signaling,
and mTORC2 is a necessary component of the Akt-
FOXO and PKCa pathways.
Introduction
The mammalian target of rapamycin (mTOR) kinase is
the catalytic subunit of at least two distinct signaling
complexes, referred to as mTOR complex 1 (mTORC1)
and mTOR complex 2 (mTORC2) (Guertin and Sabatini,
2005). Studies with cultured cell lines indicate that the
complexes participate in different pathways and recog-
nize distinct substrates, the specificity of which is deter-
mined by unique mTOR-interacting proteins. mTORC1
controls cell growth in part by phosphorylating S6
*Correspondence: sabatini@wi.mit.eduKinase 1 (S6K1) and the eIF-4E-binding protein 1 (4E-
BP1), known regulators of protein synthesis. We re-
cently proposed that mTORC2 phosphorylates and acti-
vates Akt/PKB (Sarbassov et al., 2005), which regulates
cell proliferation, growth, survival, and metabolism. Full
activation of Akt/PKB requires phosphorylation of S473
of the hydrophobic motif, the site proposed to depend
on mTORC2, as well as phosphorylation of T308 of the
activation loop by PDK1. The clinically valuable drug ra-
pamycin specifically inhibits mTORC1 activity, although
recent studies indicate that prolonged rapamycin treat-
ment can also inhibit mTORC2 assembly and function
in some cell types (Sarbassov et al., 2006). Both com-
plexes participate in signaling pathways associated
with human diseases, including tuberous sclerosis com-
plex (TSC), lymphangioleiomyomatosis (LAM), Cowden
disease, Peutz-Jeghers syndrome (PJS), neurofibroma-
tosis, familial cardiac hypertrophy, and cancers charac-
terized by hyperactivation of PI3K/Akt (Guertin and
Sabatini, 2005; Shaw and Cantley, 2006).
The roles of mTORC1 and mTORC2 during mamma-
lian development are not well understood. In addition
to mTOR, mTORC1 contains raptor (regulatory-associ-
ated protein of mTOR) and mLST8 (also called GbL)
(Hara et al., 2002; Kim et al., 2002, 2003; Loewith et al.,
2002). mTORC2 also contains mTOR and mLST8, but in-
stead of raptor, this complex contains rictor (rapamycin-
insensitive companion of mTOR) (Jacinto et al., 2004;
Sarbassov et al., 2004). Germline disruption of mTOR
in mice causes embryonic lethality at or around implan-
tation (Gangloff et al., 2004; Murakami et al., 2004). How-
ever, when these mice were engineered, it was not
known that mTOR is part of two distinct complexes
and pathways. With this new information, it becomes
difficult to interpret the phenotypes of the mTOR null
mice because these animals lack both mTORC1 and
mTORC2 function. Thus, to determine the in vivo role
of each branch of the mTOR signaling network, we gen-
erated and characterized mice lacking the expression of
raptor, rictor, and mLST8.
Results
raptor- and mLST8-Deficient Embryos Die
at Different Stages of Development
To determine the role of mTORC1 in development, we
studied the effects of deleting mTOR, raptor, or
mLST8 on embryogenesis (targeting is described in
Figure S1; see the Supplemental Data available with
this article online). No viable null mice were obtained
from any heterozygous intercrosses, indicating that all
mTORC1 complex components are essential (Table 1).
Consistent with published reports (Gangloff et al.,
2004; Murakami et al., 2004), explanted mTOR null blas-
tocysts appear normal, but inner cell mass (ICM) and
trophoblast giant cells (TGCs) fail to expand in culture
(Figures 1A and 1B). Explanted raptor null blastocysts
also exhibit defective ICM and trophoblast cell out-
growth (Figure 1C), and although these blastocysts ex-
pand slightly more than mTOR null blastocysts, they
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the raptor and mTOR null blastocyst cultures detach
and presumably die. In contrast, explanted mLST8 null
blastocysts do not show apparent growth or prolifera-
tion defects (Figure 1D).
In vivo, mTOR-deficient embryos die around embry-
onic day 5.5–6.5 (e5.5–6.5), shortly after implantation
(Gangloff et al., 2004; Murakami et al., 2004). At this
stage of development, called the egg cylinder stage,
the ICM is normally differentiated such that embryonic
and extraembryonic regions become distinct (Figure 1E).
We examined e6.5 embryos recovered from raptor het-
erozygous intercrosses and found thatw25% (presum-
ably raptor knockouts) could implant but failed to
expand and differentiate, dying shortly thereafter (Fig-
ure 1F and Table 1). Collectively, these observations in-
dicate that while the mTORC1 components mTOR and
raptor are required to pass through the same stage in
early development, mLST8, surprisingly, is not.
By genotyping midgestation embryos obtained from
mLST8 heterozygous intercrosses, we determined that
mLST82/2 mice die around e10.5 (Table 1). Analysis
of protein extracts prepared from these embryos indi-
cates that mLST8 is undetectable in the null animals
(Figure S1). Live mLST82/2 embryos, as determined by
a beating heart, are visibly smaller than wild-type (Fig-
ure 1G) or heterozygous (not shown) embryos. The most
noticeable morphological difference between wild-type
and mLST82/2 embryos is the failed development of
Table 1. Genotyping Results from Heterozygous Intercrosses
Genoytpe e3.5a e6.5b
e8.5–
e9.5 e10.5
e11.5–
e12.5c Bornd
mTOR +/+ 6 nd nd nd nd 26
+/2 16 nd nd nd nd 40
2/2 8 nd nd nd nd 0
total 30 nd nd nd nd 66
raptor +/+ 14 nd 2 18 nd 78
+/2 32 nd 5 29 nd 162
2/2 15 9 0 0 nd 0
total 61 29 7 47 nd 240
mLST8 +/+ 13 nd 4 72 10 81
+/2 19 nd 6 156 19 151
2/2 6 nd 3 69 3 0
total 38 nd 13 297 32 232
rictor +/+ nd nd 7 76 nd 71
+/2 nd nd 14 125 nd 78
2/2 nd nd 3 54 5 0
total nd nd 24 255 49 149
nd = not determined.
a Blastocysts were PCR genotyped after analysis of outgrowth in
culture. In certain cases, mutant embryos did not yield enough
DNA for genotyping and were categorized based on phenotypic
similarity.
b Embryos at e6.5 cannot be genotyped; thus, raptor embryos are
categorized as ‘‘normal’’ or ‘‘mutant’’ based on phenotype. Most
mutant embryos have progressed toward death at this stage and
appear as disorganized apoptotic-like bodies, while, in some cases
(as shown in Figure 1), the ICM is still recognizable, but is completely
devoid of expansion.
c For the rictor-deficient embryos, knockouts were determined by
western blot. Wild-type and heterozygous embryos show similar
levels of Akt/PKB S473 phosphorylation; therefore, we did not dis-
tinguish between the two.
d Mice were weaned and genotyped from tail DNA at 21 days of age.the cephalic region of the mutant (arrows in Figure 1G).
Histological analyses indicate that the telencephalic
vesicles of mLST82/2 embryos are underdeveloped
and that, overall, these embryos resemble wild-type
e9.5 embryos (Figure 2A). Histological sections of con-
trol embryos (wild-type or heterozygous) stain strongly
for Ki-67, an immunohistochemical marker of proliferat-
ing cells, indicating that most cells are not quiescent at
this stage of development (Figure 2B). There is no clear
difference in Ki-67 staining betweenmLST82/2 embryos
or control embryos. Similarly, TUNEL analysis of histo-
logical sections indicates that while both wild-type and
mLST82/2 embryos contain some apoptotic cells in lo-
calized regions, particularly near the brachial arches
and trigeminal ganglia, there is no detectable increase
in the number of apoptotic cells in mutant embryos
(Figure 2C). Thus, the developmental delay phenotype
ofmLST82/2 embryos is neither the result of cells exiting
the cell cycle nor of increased rates of apoptosis. We
conclude that mLST8 null embryos do not resemble
their raptor or mTOR null counterparts.
mLST8-Deficient Embryos Exhibit Defective
Vascular Development
The timing of death for the embryos deficient in mLST8
coincides with a period of dramatic expansion and re-
modeling of the vasculature. Strikingly, the yolk sac vas-
culature of the mLST82/2 embryos is severely defective
(Figure 2D). Compared to wild-type yolk sacs, the major
branch of the vitelline vessels in some null embryos is
underdeveloped, while in others it is undetectable. The
overall structure of e10.5 mutant placenta is intact and
the spongiotrophoblast, TGC, and labyrinth layers are
clearly detectable by H&E staining (Figure 2E). The
TGC-labyrinth interface is somewhat disorganized in
the mutants, and the labyrinth layer also appears thicker
than in control placenta (Figure 2E). This suggests that
defective exchange of nutrients and oxygen between
the mother and fetus is likely a primary cause of lethality
at e10.5. The heart is clearly beating in e9.5–10.5
mLST82/2 embryos, and histological analysis of trans-
verse sections through the midthoracic region reveals
that the general heart architecture appears normal; how-
ever, as suggested in Figure 2A, the overall embryo is
developmentally delayed (Figure 2F). The cardiac wall in
the null animal does appear to be slightly thinner when
compared to an e9.5 developmentally matched control
embryo, and internal hemorrhaging is occasionally ob-
served. Dorsal aortae and cardinal veins are present,
but when we examined the vasculature by whole-mount
PECAM-1/CD31 immunohistochemistry, we found that
blood vessels, particularly in the head, are dilated in
null animals (Figure 2G). Collectively, these observations
suggest that mLST8-deficient embryos likely die as a re-
sult of multiple defects in fetal vascular system develop-
ment. Interestingly, this phenotype is similar to the phe-
notype of mice deleted for phosphoinositide 3-kinase
(p110a) as well as for the tunica intima endothelial kinase
2 receptor tyrosine kinase (Tie2) (Bi et al., 1999; Lelievre
et al., 2005; Sato et al., 1995). Tie2, when activated by
its ligand, Angiopoietin-1, signals through PI3K to regu-
late vascular development (Kim et al., 2000; Papapetro-
poulos et al., 2000). Our results suggest that mLST8
might have an important role in this process.
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861Figure 1. mTOR- and raptor-Deficient Embryos Die Early in Development, while Embryos Lacking mLST8 or rictor Die in Midgestation
(A–D) (A) Wild-type, (B)mTOR2/2, (C) raptor2/2, or (D)mLST82/2blastocysts were explanted at e3.5 and were grown in culture for 7 days. Images
are of explanted blastocysts at 1 (e3.5 + 0.5), 4 (e3.5 + 4), and 7 (e3.5 + 7) days postharvest and are shown at 4003 and 1003magnification where
indicated. Inner cell mass (ICM), blastocoelic cavity (BC), and trophoblast giant cells (TGCs) are indicated on the control. Scale bars are 50 mm.
(E and F) e6.5 decidua were sectioned and stained with H&E. A (E) control and (F) raptor2/2 embryo are shown for comparison. Maternal decidual
tissue (D), an egg cylinder-stage embryo (EC), the embryonic ectoderm (EE), and the embryonic region (E) are indicated.
(G) e10.5 wild-type and mLST82/2 embryos. White arrows point to the cephalic region.
(H) e10.5 wild-type and rictor2/2 embryos.
(I) mLST8+/2 and rictor+/2 embryos at e10.5 stained for b-galactosidase activity. Black arrows point to intersomitic vessels.
Scale bars are 1 mm in (G)–(I).mTORC1 Signaling Does Not Require mLST8
The observation that mLST8-deficient embryos do not
phenocopy those deficient for mTOR or raptor is sur-
prising because mLST8 is a stable component of both
complexes, and we and others previously found that
acute RNAi-mediated reduction of mLST8 expressionsuppressed the phosphorylation of mTORC1 substrates
in tissue culture cells (Jacinto et al., 2004; Kim et al.,
2003) (see Discussion). A potential explanation for why
embryos lacking mLST8 are different from those miss-
ing mTOR or raptor is that mLST8 is not required for
mTORC1 signaling during early mouse development,
Developmental Cell
862Figure 2. Phenotypic Characterization of mLST8-Deficient Embryos
(A–C) Transverse serial sections through the optic level of e10.5 litter-matched (i)mLST8+/2 and (ii)mLST82/2 embryos, and an (iii) e9.5mLST8+/2
embryo developmentally matched to the e10.5 null embryos. (A) Sections were H&E stained and imaged at 403 magnification. The fourth
ventricle (FV), trigeminal ganglion (TG), brachial arch (BA), lens pit (LP), and telencephalic vesicle (TV) are marked. (B) Sections were labeled
with Ki-67. Images are at 1003 magnification. The dotted box in (A) indicates the location of the Ki-67-stained image relative to the section.
(C) Sections were TUNEL stained and were imaged at 403 magnification. The first image is labeled as in (A) for orientation.
(D) Representative images of yolk sacs from a wild-type (+/+) and two mLST8-deficient (2/2) embryos. Arrows point to the major branch of the
vitelline vessels. Some null embryos have underdeveloped vitelline vessels (middle), while others lack the major branch (right).
(E) H&E stains of control (+/+) and mLST8 mutant (2/2) placenta from e10.5 embryos. Spongiotrophoblast (S), trophoblast giant cell (TGC), and
labyrinth (L) layers are indicated.
(F) H&E-stained transverse sections through the midthoracic region of e10.5 mLST8 heterozygous (+/2) or null (2/2) embryos. A developmen-
tally matched e9.5 control embryo is included for comparison. The dorsal aorta (DA), the cardinal vein (CV), the trachea (T), the atrial chamber
(AC), and the ventricular canal (VC) are marked. Images are at 403 magnification.
(G) Whole-mount immunohistochemistry with anti-PECAM1/CD31 antibody. The heads of onemLST8+/+ and twomLST82/2 embryos are shown.
Arrows point to major vessels that are dilated in mLST8-deficient embryos. The scale bar is 500 mM.but is required for cells growing in culture. To test this
possibility, we examined the activity of the mTORC1
pathway in protein lysates prepared from mLST82/2
mouse embryo fibroblasts (MEFs). Immunoblot analy-
ses reveal that basal phosphorylation of S6K1 at T389
is normal in these MEFs (Figure 3A; additional evidence
in Figure S3). Phosphorylation of S6, an S6K1 substrate
and surrogate reporter for mTORC1 activity, is also un-
affected by the mLST8 deletion (see Figure 5E and
Figure S3B). Furthermore, the loss of mLST8 does not
affect the phosphorylation of 4E-BP1 (Figure 3B).
We next asked if mLST8 is necessary for S6K1 phos-
phorylation in response to insulin or serum stimulation
(Figure 3C). Serum deprivation reduces basal S6K1
phosphorylation on T389, which is reactivated by a brief
treatment with insulin or serum, and this regulation oc-curs normally in mLST82/2 cells. We also determined
that mLST8 is not necessary for rapamycin to inhibit or
for nutrients to regulate mTORC1 signaling (Figure 3D).
Rapamycin inhibited S6K1 T389 phosphorylation to the
same extent in MEFs with or withoutmLST8. Likewise, in
both control and mLST8 null MEFs, leucine deprivation
caused a mild reduction in S6K1 phosphorylation that
was reversed by leucine readdition. These results lead
us to conclude that mLST8 null cells do not exhibit
defects in canonical mTORC1 signaling.
rictor- andmLST8-Deficient Mice Are Phenotypically
Similar, and Both rictor and mLST8 Are Necessary
for Akt/PKB S473 Phosphorylation
Having failed to find a need for mLST8 in mTORC1
signaling, we examined its necessity for the in vivo
mTOR Signaling in Mouse Development
863Figure 3. mLST8 Is Required for Akt/PKB, but Not S6K1, Signaling
(A) Immunoblot of mTOR complex components and their downstream substrates, Akt/PKB and S6K1, in mLST82/2 MEFs. MEFs prepared from
wild-type (+/+) and heterozygous (+/2) littermates and rapamycin (RAP)- and LY-treated (+/2) MEFs are shown as controls.
(B) 4E-BP1 phosphorylation and the total 4E-BP1 protein level in control and mLST82/2 MEFs.
(C) Akt/PKB S473 and S6K1 T389 phosphorylation in control or mLST82/2MEFs after serum deprivation (starved) or serum deprivation followed
by insulin or serum (FBS) readdition to the media.
(D) Akt/PKB S473 and S6K1 T389 phosphorylation in control and null MEFs after rapamycin treatment (+RAP), leucine deprivation (2LEU), or
leucine deprivation followed by restimulation (2/+LEU).functions of mTORC2 by comparing embryos and MEFs
null for mLST8 with those lacking rictor. Interestingly,
like mLST82/2 embryos, rictor2/2 embryos are develop-
mentally delayed, exhibit phenotypic characteristics
similar to mLST82/2 embryos, and die around e10.5
(Figure 1H, Figure S2, and Table 1). Both the mLST8-
and rictor-targeting constructs placed the b-galactosi-
dase gene under control of the respective endogenous
promoters (Figure S1), allowing us to use X-gal staining
of heterozygous embryos to determine the expression
patterns of each gene. Both mLST8 and rictor are ex-
pressed in an overlapping pattern throughout the de-
veloping embryo (Figure 1I). mLST8+/2 embryos stain
slightly more intensely in the cephalic region, although
both exhibit strong staining in intersomitic vessels.
Immunoblot analyses of protein lysates prepared from
both mLST8- and rictor-deficient MEFs reveal that both
gene products are necessary for the basal (Figures 3A
and 4A), serum-stimulated (Figures 3C and 4B), and in-
sulin-stimulated (Figures 3C and 4C) phosphorylation
of Akt/PKB on S473 of its hydrophobic motif. The lossof Akt/PKB S473 phosphorylation in MEFs missing
mLST8 or rictor validates previous biochemical and
loss-of-function results in cultured cells, indicating that
mTORC2 is the principal S473 kinase of Akt/PKB (Hre-
sko and Mueckler, 2005; Sarbassov et al., 2005). Unex-
pectedly, the loss of mLST8 or rictor did not strongly
affect the phosphorylation of Akt/PKB on T308 of the
activation loop, which is phosphorylated by PDK1 (Fig-
ures 3A and 4A). Furthermore, regulation of Akt/PKB
T308 phosphorylation by insulin is normal in mTORC2-
deficient MEFs (Figure 4C). We detect a mobility shift
when immunoblotting for either Akt/PKB T308 or total
Akt/PKB when Akt/PKB lacks only S473 phosphoryla-
tion (Figures 3A and 4A). This is consistent with previous
observations that Akt/PKB mobility is sensitive to the
charge associated with its phosphorylation sites (Alessi
et al., 1996; Sarbassov et al., 2006). To confirm that
the lack of S473 phosphorylation and not the absence
of an unknown posttranslational modification caused
the shift, we expressed the Akt S473D mutant in
mTORC2-deficient cells (Figure 4D). As expected, the
Developmental Cell
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(A) Immunoblot of mTOR complex components, Akt/PKB, and S6K1 in rictor2/2 MEFs.
(B) Akt/PKB S473 phosphorylation in control or rictor2/2 MEFs after serum deprivation (starved) or restimulation with serum (starved/+FBS).
(C) Regulation of Akt/PKB and S6K1 in rictor2/2 MEFs after serum deprivation (starved) and restimulation with insulin (starved/+insulin).
(D) The phospho-mimicking Akt/PKB S473D mutant does not increase mobility in mTORC2-deficient cells. Recombinant Akt S473D or wild-type
Akt was expressed inmLST8 null MEFs by using an MSCV viral expression system. InmLST82/2 cells, the mobility of recombinant wild-type Akt,
which is S473 deficient, increases (bottom arrows). In contrast, the mobility of the recombinant Akt S473D mutant inmLST82/2 cells is identical to
endogenous Akt mobility in control (+/2) cells (top arrows).
(E) Immunoblot of mTOR complex components and Akt/PKB phopsphorylation states in lysates prepared from whole, individual control (+/+ and
+/2) and mLST8 or rictor null (2/2) embryos.
mTOR Signaling in Mouse Development
865phospho-mimicking S473D mutation completely res-
cues the mobility shift, consistent with mTORC2 phos-
phorylating S473.
The identity of the Akt/PKB S473 kinase has been con-
troversial, and because we undertook the preceding
biochemical experiments in vitro with cultured primary
fibroblasts, it seemed possible that another S473 kinase
might phosphorylate Akt/PKB in embryos in which many
cell types are present. To determine if there is a compen-
satory Akt/PKB S473 kinase present in whole embryos,
we immunoblotted lysates prepared from control, rictor,
and mLST8 null embryos for Akt/PKB S473 phosphory-
lation. We find no evidence of a compensatory Akt/PKB
S473 kinase in whole embryos (Figure 4E). Thus,
mTORC2 is likely the key regulator of Akt/PKB S473
phosphorylation in vivo.
Phosphorylation of FOXO3, but Not TSC2 or GSK3b,
Depends on rictor and mLST8
We next asked if ablating mTORC2 function affects the
phosphorylation of known Akt/PKB substrates. Either
rictor- ormLST8-deficient MEFs were deprived of serum
and then stimulated with insulin, and the phosphoryla-
tion state of three Akt/PKB substrates, GSK3b, TSC2,
and FOXO3, was determined. Ablation of rictor or
mLST8 does not affect the regulation of the Akt/PKB
phosphorylation site S9 on GSK3b (Figure 5A). We ex-
amined two predicted Akt/PKB phosporylation sites
on TSC2—T1462 and S939. Surprisingly, both sites are
also phosphorylated in response to insulin stimulation
in control, rictor null, and mLST8 null cells (Figure 5B).
In control cells, stimulation also induces phosphoryla-
tion of FOXO3 on the Akt/PKB phosphorylation site
T32 (Figure 5B; additional evidence in Figure S3). How-
ever, in contrast to GSK3b and TSC2 phosphorylation,
the stimulated increase in FOXO3 T32 phosphorylation
is substantially reduced in the rictor and mLST8 null
MEFs (Figure 5B and Figure S3). These results indicate
that in primary mouse fibroblasts, loss of mTORC2 func-
tion differentially affects the phosphorylation of pre-
dicted Akt/PKB substrates.
It is well documented that S473 phosphorylation of
Akt/PKB is important for full kinase activity, but because
GSK3b and TSC2 are popular Akt/PKB substrates, we
wondered if loss of Akt/PKB S473 phosphorylation in
MEFs reduced its catalytic activity. We measured the
in vitro kinase activity of serum-stimulated Akt/PKB im-
munoprecipitates isolated from rictorormLST8null cells
(Figure 5C). Despite the fact that equal amounts of Akt/
PKB are present in each reaction, deletion of either rictor
or mLST8 reduces the serum-stimulated in vitro kinase
activity of Akt/PKB to about 10%–15% of serum-stimu-
lated controls (Figure 5C). This is roughly the same level
of Akt/PKB activity recoverable from serum-deprived
control cells and confirms the importance of S473 phos-
phorylation for Akt/PKB catalytic activity (Alessi et al.,
1996). Thus, mTORC2-dependent phosphorylation of
Akt/PKB at S473 is required for its in vitro activity.
rictor and mLST8 Are Required to Maintain
PKCa Phosphorylation and Expression,
but Not Cytoskeletal Integrity
Akt/PKB, S6K1, and SGK belong to the AGC family of
kinases, which also includes RSK and PKCa (Hanadaet al., 2004). Each contains a PDK1 phosphorylation
site in the activation loop and a hydrophobic motif phos-
phorylation site. Because mTORC1 and mTORC2 phos-
phorylate the hydrophobic motif sites of S6K1 and Akt/
PKB, respectively, we wondered if mTORC2 has an ad-
ditional role in phosphorylating other hydrophobic mo-
tifs. Unfortunately, the immunoblot signals for the hy-
drophobic motif phosphorylation sites SGK S422 and
RSK S380, determined by using commercially available
antibodies, were not robust enough for us to trust the
quality of the antibodies; thus, we could not determine
the role of mTORC2 in their regulation (data not shown).
In contrast, PKCa phosphorylation on S657 as well as
total protein levels are severely reduced in both rictor
and mLST8 null MEFs compared to controls (Figure 5D).
This is consistent with a previous report suggesting that
mTORC2 is necessary for PKCa S657 phosphorylation
and that phosphorylation of this site is necessary to
maintain PKCa stability (Bornancin and Parker, 1997;
Edwards and Newton, 1997; Sarbassov et al., 2004).
Early RNAi experiments in NIH 3T3 and HeLa cells
suggested that mTORC2 regulates the actin cytoskele-
ton (Jacinto et al., 2004; Sarbassov et al., 2004). More-
over, PKCa regulates numerous processes, one of which
is cytoskeleton dynamics (Larsson, 2006). We suspected
that this might not be the case in rictor- or mLST8-defi-
cient cells because they spread and divide normally in
culture (data not shown). To test this experimentally,
we analyzed actin and tubulin in rictor- and mLST8-
deficient cells. There are no differences in either actin or
microtubule staining between wild-type and rictor2/2
or mLST82/2 MEFs (Figure 5E). Thus, maintenance of
cytoskeletal integrity is not a critical downstream func-
tion of mTORC2 in primary mouse fibroblasts.
mLST8 Is Required to Maintain the rictor-mTOR,
but not the raptor-mTOR, Interaction
Comparative analysis of raptor-, mLST8-, and rictor-
deficient embryos at the organismal, cellular, and sub-
cellular levels suggests that mLST8 is required for
mTORC2 function in mammalian development but is
dispensable for mTORC1 functions. Because mLST8 is
a stable component of both complexes, we wondered
what might be the mechanism through which mLST8
specifically perturbs mTORC2 when deleted. Using an
antibody to raptor, we immunopurified mTORC1 com-
plexes from control or mLST8 null cells. Loss of mLST8
did not impair the raptor-mTOR interaction, as seen
from the equal amounts of mTOR that are recovered
in raptor immunoprecipitates from both control and
mLST8 null cells. Consistent with mLST8 not being re-
quired for mTORC1 activity, raptor immunoprecipitates
isolated from mLST8 null cells phosphorylate S6K1 at
T389 as efficiently as immunoprecipitates prepared
from control cells in an in vitro kinase assay (Figure 6A).
Control b-catenin immunoprecipitates show no activity
toward S6K1, indicating that the activity is specific to
mTORC1. These results substantiate our previous find-
ings and are consistent with mLST8 not being required
for canonical mTORC1 functions in MEFs.
We next checked if mLST8 was required for mTORC2
activity in vitro. Using an antibody to rictor, we immuno-
purified mTORC2 from control and mLST8 null cell ly-
sates and assayed its ability to phosphorylate Akt/PKB
Developmental Cell
866Figure 5. mTORC2 Is Required for Akt/PKB-FOXO3 and PKCa Signaling
(A) Insulin-dependent regulation of GSK3b S9 phosphorylation in control, rictor2/2, and mLST82/2 MEFs.
(B) Insulin-dependent regulation of TSC2 T1462, TSC2 S939, and FOXO3 T32 phosphorylation in control, rictor2/2, and mLST82/2 MEFs.
(C) In vitro Akt/PKB kinase activity assay. Akt/PKB was isolated from control, serum-deprived (starved), or stimulated (+FBS) MEFS, as
well as from rictor2/2- or mLST82/2-stimulated MEFs. The ability of immunopurified Akt to incorporate radiolabeled phosphate into
mTOR Signaling in Mouse Development
867Figure 6. mLST8 Is Required for the rictor-mTOR, but Not the raptor-mTOR, Interaction
(A) raptor or b-catenin immunoprecipitates were prepared from control or mLST82/2 MEFs, and their ability to phosphorylate purified S6K1 at
T389 was measured. An immunoblot for mTOR and raptor in each immunoprecipitate is shown.
(B) rictor or b-catenin immunoprecipitates were prepared from control or mLST82/2MEFs, and their ability to phosphorylate purified Akt at S473
was determined. An immunoblot for the levels of mTOR and rictor in each immuoprecipitate is shown.
(C) mTOR was immunoprecipitated from control or mLST82/2MEFs. The ability of mTOR to bind raptor (left) and rictor (right) was determined by
probing immunoprecipitates with mTOR and either raptor- or rictor-specific antibodies.at S473 in vitro. The loss of mLST8 completely abro-
gates the interaction between rictor and mTOR, as no
mTOR coimmunoprecipitates with rictor from knockout
cells (Figure 6B). As is expected, loss of the rictor-mTOR
interaction prevented rictor immunoprecipiates from
phosphorylating Akt/PKB S473 in vitro. Interestingly,
the mLST8 deletion increases rictor mobility by SDS-
PAGE, suggesting that mLST8 might also be required
for a posttranslational modification of rictor, which re-
mains unidentified but is likely to be phosphorylation
(Sarbassov et al., 2004).
These experiments suggest that mLST8 functions to
maintain a stable association between rictor and
mTOR, which is required for mTOR to be able to phos-
phorylate Akt/PKB in cells. To further test this hypothe-
sis, we performed the reciprocal experiment in which
mTORC1 and mTORC2 were immunopurified from con-
trol and mLST8 knockout cells by using an antibody
to mTOR. As is the case with the raptor immunoprecip-
itations, mTOR immunoprecipitates from control and
mLST8 null cells contain equal amounts of raptor (Fig-
ure 6C). Consistent with rictor immunoprecipitations,
the loss of mLST8 completely disrupts the ability of
mTOR to pull-down rictor. This confirms that mLST8
has a key role in maintaining mTORC2, but not mTORC1,
integrity. Our previous work indicates that in trans-
formed cells the increased stability of the raptor-mTOR
interaction caused by leucine deprivation depends on
mLST8 (Kim et al., 2003). Because leucine only weakly
regulates the mTORC1 pathway in MEFS (Figure 3D),
a role for mLST8 in stabilizing the raptor-mTOR inter-
action may not be apparent in these cells.Discussion
To determine the role of mTORC1 and mTORC2 in vivo,
we generated mice deficient for raptor, rictor, and
mLST8. Our results indicate that, similar to mice lacking
mTOR, mice lacking raptor, which defines mTORC1, die
around the time of implantation, while mice lacking ric-
tor, which defines mTORC2, die around midgestation.
Unexpectedly, mice deficient for mLST8 are phenotypi-
cally similar to mice deficient for rictor. Both rictor and
mLST8 are required for Akt/PKB S473 phosphorylation,
Akt/PKB kinase activity, insulin-stimulated phosphory-
lation of FOXO3, and PKCa phosphorylation and protein
levels. Although mLST8 is a component of both mTOR
complexes, it is essential to maintain the rictor-mTOR,
but not the raptor-mTOR, association, thus explaining
the similarities between mLST8- and rictor-deficient
embryos and cells. We conclude that during mammalian
development, mTORC1 and mTORC2 have different, but
essential, roles; that mLST8 is required only for mTORC2
function; and that mTORC2 is a crucial component of the
Akt/PKB-FOXO and PKCa signaling networks.
mTORC1 Is Required Early in Development
The first mTOR-deficient mice described were gener-
ated by ethyl-nitroso-urea (ENU) mutagenesis and
were hypomorphic (Hentges et al., 2001). These animals
exhibited defects in telencephalon development and
died at e11.5 from an apparent failure to turn (Hentges
et al., 1999). Two subsequent studies employing gene-
targeting strategies found that mTOR is required early
in development and that mTOR-deficient embryos diea synthetic Akt-specific substrate peptide was measured. A loading control for total levels of Akt in the assay is shown. Bars indicate
standard error.
(D) Immunoblot for insulin-dependent PKCa phosphorylation at the S657 hydrophobic motif site, and for total PKCa protein in control,
rictor2/2, and mLST82/2 MEFs.
(E) Staining for actin, phospho-S6 (as a marker for mTORC1 activity), and a-tubulin in control, rictor2/2, and mLST82/2 MEFs.
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kami et al., 2004). Consistent with proliferation defects,
explanted mTOR null blastocysts looked normal, but
when grown in culture, these cells exhibited little tropho-
blast outgrowth, which arrested within a few days
(Gangloff et al., 2004). When these observations were re-
ported, it was thought that mTOR functioned as part of
one complex containing raptor and mLST8 (the complex
now named mTORC1). With the discovery of mTORC2,
the interpretation of the mTOR2/2 phenotype became
complicated because it was unclear which functions of
mTOR were required in early development. Here, we re-
port a knockout of raptor, a key regulator of mTORC1
functions, as well as a third mTOR knockout. We found
that raptor-deficient embryos die shortly after implanta-
tion and that explanted raptor2/2 blastocysts show the
same proliferation defects associated with the previ-
ously published mTOR2/2 mice and the one described
here. mTORC1 is thought to be a nutrient- and rapamy-
cin-sensitive complex, and raptor is thought to be a key
regulator of the nutrient-sensitive mTOR response (Hara
et al., 2002; Kim et al., 2002; Loewith et al., 2002). A pre-
vious study found that amino acids have a particularly
important role in regulating trophoblast differentiation
in an mTOR-dependent manner (Martin and Sutherland,
2001). Moreover, rapamycin disrupts normal blastocyst
outgrowth in culture (Gangloff et al., 2004; Murakami
et al., 2004). Considering these findings, our discovery
that raptor2/2 embryos are similar to those null for
mTOR suggests that the early lethality associated with
mTOR2/2mice is the result of losing mTORC1 functions.
mLST8 Is Not Required for mTORC1 Functions
in Mouse Development
In this report, we provide the first, to our knowledge, de-
scription of a mouse deleted for the mLST8 gene, which
encodes a component of both mTORC1 and mTORC2
(Jacinto et al., 2004; Kim et al., 2003; Loewith et al.,
2002; Sarbassov et al., 2004). Previous studies from our
group and the Hall group used early-generation siRNAs
to partially knock down mLST8 expression and found
that mLST8 was required for mTORC1 signaling in two
immortalized cell lines (HEK-293T and NIH 3T3) (Jacinto
et al., 2004; Kim et al., 2003). Therefore, it was unex-
pected when we observed that mLST82/2 blastocysts
do not mirror mTOR2/2 or raptor2/2 blastocysts when
grown in culture. This suggested to us that mLST8 is not
required for the same biological processes as mTOR
and raptor in development. We then showed in primary
mouse fibroblasts deficient for mLST8 that mTORC1
signaling to S6K1 and 4E-BP1 is normal, that the raptor-
mTOR interaction is unimpaired, and that purified
mTORC1 complexes can efficiently phosphorylate S6K1
in vitro.
One possible reason for the discrepancy with previ-
ous studies is that in the mLST8 knockout, another
G-b-like protein can substitute for mLST8 in mTORC1.
We have analyzed mTORC1 complexes purified from
control and mLST82/2 cells by SDS-PAGE followed by
silver staining. We observe the disappearance of the
mLST8 band from mTORC1 complexes purified from
the null cells, and although we do not see any obvious
‘‘substitute’’ protein, we cannot rule out the possibility
that an undetectable protein(s) is bound and mediatesthe function of mLST8 (data not shown). Alternatively,
a mechanism could exist in vivo or in primary cells that
allows mTORC1 to overcome the loss of mLST8. This
speculation seems reasonable because embryos might
exhaust all possible resources to overcome a defect that
threatens viability; however, at the moment, it is difficult
to predict what such a mechanism might be. By their na-
ture, cultured cancer cells are vastly different than whole
embryos or primary cells, and a compensatory mecha-
nism could be absent in these cancer cells. It is also im-
portant to remember that RNAi experiments only elicit
acute loss of gene expression, and that often it is not
very robust, which is the case with our early siRNA ex-
periments (no mLST8 knockdown expression data are
provided in the Jacinto et al. [2004] report) (Kim et al.,
2003). One must consider that a knockdown in a cultured
cancer cell is different than a knockout in a mouse, and
that our observations may reflect the disparity between
partial versus complete elimination ofmLST8 gene func-
tion. Interestingly, a decrease in dS6K phosphorylation
is not observed after RNAi-mediated depletion of Dro-
sophila LST8 in cultured S2 cells (data not shown)
(Yang et al., 2006).
mTORC2 Is Required at Midgestation
Less is known about the more recently discovered
mTORC2. In addition to mTOR, mTORC2 contains
mLST8 and rictor (Jacinto et al., 2004; Sarbassov
et al., 2004). Recently, we found that mSIN1 is an addi-
tional component of mTORC2, and while this manu-
script was under review, another study reported similar
conclusions (Frias et al., 2006; Jacinto et al., 2006).
Based on loss-of-function analysis in Drosophila and
human cultured cells combined with in vitro biochemical
studies, we previously proposed that mTORC2 is the
S473 kinase of Akt/PKB (Sarbassov et al., 2005). Unlike
its mTORC1 counterpart, mTORC2 is generally insensi-
tive to rapamcyin, but, interestingly, we find that in
some cell types, prolonged treatment with rapamycin
can inhibit mTORC2 assembly and Akt/PKB phosphory-
lation (Sarbassov et al., 2006).
In this study, we found that mLST8- and rictor-defi-
cient embryos die around e10.5. The fact that both dele-
tions result in embryonic lethality at the same time sug-
gests that loss of mLST8 specifically impairs mTORC2
function. We confirmed this by showing that mTORC2-
dependent phosphorylation of Akt/PKB S473 is absent
in both mLST8 and rictor null embryos and primary fi-
broblasts, and that mLST8 is required for maintaining
the rictor-mTOR interaction, providing a probable expla-
nation for their phenotypic similarity. The exact cause of
death in mLST82/2 and rictor2/2 embryos is not clear,
but phenotypic analysis suggests that null embryos
likely die from defective fetal vascular development.
While this manuscript was under review, a study by
Shiota et al. (2006) independently described an addi-
tional rictor knockout mouse. Analyses of the placental
component of the fetal vascular system, both in our
study and in that by Shiota et al., reveal a defect in the
organization of the maternal-fetal interface in mLST8
and rictor knockouts. However, the three major placen-
tal layers (spongiotrophoblast, TGC, and labyrinth) still
form, leading us to speculate that loss of rictor might
cause additional defects. Shiota et al. test this idea by
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showing that rictor is still essential for progressing
though midgestation (Shiota et al., 2006). Interestingly,
we find additional defects in the yolk sac and embryonic
vasculature ofmLST82/2mice, perhaps suggesting that
loss of mTORC2 might have a more global affect on the
vascular system.
A common conclusion of our report and those by Ja-
cinto et al. and Shiota et al. is that inactivation of
mTORC2 by deleting the genes for mLST8, rictor, or
mSIN1 suppresses the phosphorylation of Akt/PKB on
S473. Collectively, these reports validate our earlier
work in Drosophila and human cancer cells (Sarbassov
et al., 2005) as well as the work of others in mouse adi-
pocytes (Hresko and Mueckler, 2005), and they provide
strong genetic evidence in animals supporting a role for
mTORC2 as the main hydrophobic motif kinase of Akt/
PKB. An unexpected finding of all three reports is that
ablation of Akt/PKB S473 phosphorylation did not result
in a strong reduction in Akt/PKB T308 phosphorylation.
This is surprising because RNAi-mediated knockdown
of rictor reduced T308 phosphorylation in tandem with
that of S473 in multiple cell types (Hresko and Mueckler,
2005; Sarbassov et al., 2005). The current observations
may reflect differential regulation of PDK1 in different
cell types or the different phenotypes caused by a parti-
al versus a complete reduction in gene expression. The
persistent Akt/PKB T308 phosphorylation in mLST8-
and rictor-deficient MEFs is not likely a result of up-
regulated PDK1 activity because we find that PDK1-
mediated phosphorylation of S6K1 on T229 is similar
in control and rictor-deficient cells (see Figure 4C).
The dependency of T308 phosphorylation of Akt/PKB
on S473 phosphorylation has been a controversial issue.
Using immortalized cells Scheid et al. (2002) proposed
that prior phosphorylation at S473 is necessary for
PDK1 to phosphorylate T308. The Alessi group found
that prior phosphorylation of the hydrophobic motif
sites of two kinases structurally related to Akt/PKB,
S6K1 and SGK, is necessary for PDK1 to subsequently
phosphorylate each kinase in the activation loop (Biondi
et al., 2001). However, they found that this was not the
case for Akt/PKB, suggesting that the phosphorylation
of S473 is not critical for that of T308. The fact that
Akt/PKB T308 phosphorylation is unaffected by loss of
S473 phosphorylation in mTORC2-deficient embryos
and MEFs is consistent with these results and suggests
that Akt/PKB phosphorylation by PDK1 within animals
does not require an interaction between the PDK1 PIF
pocket and the phosphorylated hydrophobic motif. It
would be interesting if in transformed, but not normal,
cells S473 phosphorylation is required for T308 phos-
phorylation, as it would suggest that inhibition of
mTORC2 in tumors would have a greater effect on Akt/
PKB signaling than in normal tissues.
While our results clearly show that mTORC2 is re-
quired for Akt/PKB regulation, we additionally show
that mTORC2 is required for other Akt/PKB-indepen-
dent pathways that may contribute to embryonic lethal-
ity (discussed below). Three Akt/PKB genes with redun-
dant functions exist in mammals (Akt1/PKBa, Akt2/
PKBb, and Akt3/PKBg), and genetic disruption of any
one Akt/PKB gene results in viable animals (Chen
et al., 2001; Cho et al., 2001; Easton et al., 2005; Garofaloet al., 2003). Akt1/PKBa Akt2/PKBb double knockouts
are severely growth impaired but survive to birth, dying
shortly thereafter (Peng et al., 2003). Mice lacking Akt2/
PKBb and Akt3/PKBg are also viable (Dummler et al.,
2006). In contrast, Akt1/PKBaAkt3/PKBg double knock-
outs die around e11.0–12.0 and exhibit severe defects in
cardiovascular and nervous system development (Yang
et al., 2005), perhaps reflecting the eventual outcome of
some of the placental-independent defects we observe
in mLST8-deficient embryos. It will be interesting to
eventually compare mTORC2-deficient mice with Akt/
PKB triple knockouts.
mTORC2 Inactivation Differentially Affects Signaling
to Akt/PKB Effectors
Our study shows that ablating mTORC2 function in
MEFs by deleting mLST8 or rictor impaired insulin-
stimulated FOXO3 phosphorylation on T32, a predicted
Akt/PKB phosphorylation site. In contrast, the phos-
phorylation of two other predicted Akt/PKB substrates,
TSC2 and GSK3b, responded normally to insulin stimu-
lation in both knockout cells. Jacinto et al. (2006) report
similar findings in mSIN1-deficient MEFs. This could
suggest that S473-deficient Akt/PKB retains enough
catalytic activity to phosphorylate some, but not all, of
its substrates. Using immunoblot-based in vitro assays,
Jacinto et al. (2006) and Shiota et al. (2006) suggest that
S473-deficient Akt/PKB is reduced in activity, but not
quite to the same extent as Akt/PKB in serum-deprived
cells. In our study, we used a quantitative assay to mea-
sure S473-deficient Akt/PKB activity, and we find that it
is roughly equivalent to the Akt/PKB activity present in
serum-starved cells. These different results could reflect
the differences in analytical capacity between the two
types of experiments. Alternatively, it might reflect the
fact that we deprive MEFs of serum for only 4 hr to avoid
potential unwanted negative or compensatory effects
associated with long-term starvation, while the other
studies deprived cells of serum for 12 hr, plus an addi-
tional hour in PBS in the case of Jacinto et al. Regard-
less, these findings might suggest that not all predicted
targets of Akt/PKB require S473 phosphorylation. Alter-
natively, these observations could indicate that a substi-
tute kinase may exist in mouse primary fibroblasts for
certain, but not all, Akt/PKB substrates. It may be possi-
ble, for example, that an unknown kinase can substitute
for Akt/PKB in phosphorylating TSC2 or GSK3b. This is
not unreasonable considering that the Akt/PKB phos-
phorylation motif is similar to that of other kinases. For
example, recent work suggests that a site on mTOR
thought to be phosphorylated by Akt/PKB may in fact
be an S6K1 phosphorylation site (Chiang and Abraham,
2005; Holz and Blenis, 2005).
In MEFs, mTORC2 Regulates PKCa Phosphorylation
and Stability, but Not the Actin Cytoskeleton
PKC isoforms are thought to be important regulators
of many intracellular signaling pathways and biological
functions, including regulating the cytoskeleton (Lars-
son, 2006). We previously suggested that PKCa phos-
phorylation might be regulated by mTORC2 (Sarbassov
et al., 2004), and in this study we clearly show that abla-
tion of mLST8 or rictor severely compromises PKCa
phosphorylation and stability. Importantly, this confirms
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by mTORC2. Previous studies indicate that mTORC2
regulates the actin cytoskeleton in HeLa and NIH 3T3
cells (Jacinto et al., 2004; Sarbassov et al., 2004), and
we suspected that this regulation might occur through
PKC family proteins. However, we find that mLST82/2
and rictor2/2 MEFs have normal actin and microtubule
organization despite the negative effects on PKCa.
PKCa is regarded as the most ubiquitously expressed
PKC isoform; however, PKCa null mice look normal and
are viable and fertile despite having defects in glucose
transport (Leitges et al., 2002). Thus, the consequence of
losing PKCa phosphorylation in development is unclear.
Concluding Remarks
In this study, we generated mice deficient for raptor,
mLST8, or rictor to determine the role of mTORC1 and
mTORC2 in vivo. We conclude that raptor is an essential
component of mTORC1 and is required, along with
mTOR, early in development. Unexpectedly, we find that
mLST8 is an essential component of mTORC2, but not
mTORC1, and that mTORC2 is required in midgestation.
Part of the motivation behind this study was to validate
our previous work with cultured cells in a vertebrate
model organism. An important theme that emerged from
this work is that partial loss of gene expression in cul-
tured cells by RNAi can be a powerful method of assign-
ing gene function (as is the case with raptor and rictor),
but it cannot always substitute for genetic ablation in de-
termining the essential function of a gene in an organism
(as is the case with mLST8). The development and char-
acterization of mice deficient in raptor, mLST8, or rictor
is an important step toward understanding the in vivo
functions of the mTOR signaling network.
Experimental Procedures
Mouse Strains and Cultured Cells
Targeted alleles are described in Figure S1. All animal work was
done according to guidelines established by the Massachusetts In-
stitute of Technology Committee on Animal Care. Blastocyst harvest
and outgrowth was done according to (Dobles et al., 2000). MEFs
were grown in DMEM supplemented with 10% fetal calf serum.
Protein Analyses
Lysis of cultured MEFs was done as described by Kim et al. (2002)
with 1% Triton X-100 detergent in the buffer. Embryos were lysed
by sonication in tissue lysis buffer (50 mM HEPES [pH 7.4], 40 mM
NaCL, 2 mM EDTA, 1.5 mM sodium orthovanadate, 50 mM sodium
fluoride, 10 mM sodium pyrophosphate, 10 mM sodium b-glycero-
phosphate, 0.1% SDS, 1.0% sodium deoxycholate, and 1.0% Triton,
supplemented with protease inhibitor cocktail tablets [Roche]).
Where indicated, cells were treated with rapamycin (100 nm; Calbio-
chem) or LY (20 nm) for 30 min. For serum and insulin stimulation
experiments, cells were deprived of serum for 3 hr, then FBS or in-
sulin was added back at 23 or 280 nm concentration, respectively,
for 30 min prior to lysis. For leucine starvation, cells were briefly
rinsed in leucine-free media, then incubated in leucine-free media
for 45 min, and, where indicated, restimulated with leucine for
15 min. Akt/PKB kinase activity was measured by using the Akt1/
PKBa Immunoprecipitation Kinase Assay Kit (Upstate). mTORC
in vitro kinase assays were performed according to Sarbassov
et al. (2005). All antibodies used in this report are described in the
Supplemental Experimental Procedures.
Histological Analysis
Embryos were fixed in 4% PFA/PBS for 2–4 hr, then transferred to
70% ethanol for storage. Placentas were fixed in either Bouin’s or4% PFA/PBS. Tissue was embedded and sectioned by the Massa-
chusetts Institute of Technology Center for Cancer Research Histol-
ogy Facility. TUNEL was performed by using the In Situ Cell Death
Detection Kit, AP (Roche). For PECAM-1 immunohistochemistry,
embryos were fixed overnight in methanol/DMSO. After blocking
endogenous peroxidase activity, embryos were rehydrated and in-
cubated overnight with PECAM-1 antibody. After the addition of
secondary antibody and staining with a DAB substrate kit (Calbio-
chem), embryos were postfixed in 4% PFA/PBS and dehydrated
to 100% methanol. For Ki-67, staining after antigen retrieval was per-
formed by using the pressure cooker method. IHC staining was done
according to the Dako ARK kit with a 1:50 Ki67 Ab dilution. Actin and
tubulin detection and phospho-S6 immunofluorescence is de-
scribed by Moffat et al. (2006). Imaging techniques are described
in the Supplemental Data.
Supplemental Data
Supplemental Data include antibody information, imaging tech-
niques, and gene-targeting strategies and are available at http://
www.developmentalcell.com/cgi/content/full/11/6/859/DC1/.
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